

Lotte Bjerre Knudsen

List of Publications by Citations

Source: <https://exaly.com/author-pdf/3563648/lotte-bjerre-knudsen-publications-by-citations.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

75
papers

7,190
citations

44
h-index

82
g-index

82
ext. papers

8,306
ext. citations

5.7
avg, IF

5.83
L-index

#	Paper	IF	Citations
75	Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration. <i>Journal of Medicinal Chemistry</i> , 2000 , 43, 1664-9	8.3	517
74	GLP-1 receptor localization in monkey and human tissue: novel distribution revealed with extensively validated monoclonal antibody. <i>Endocrinology</i> , 2014 , 155, 1280-90	4.8	445
73	The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss. <i>Journal of Clinical Investigation</i> , 2014 , 124, 4473-88	15.9	429
72	Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide. <i>Journal of Medicinal Chemistry</i> , 2015 , 58, 7370-80	8.3	406
71	Glucagon-like Peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation. <i>Endocrinology</i> , 2010 , 151, 1473-86	4.8	398
70	The long-acting GLP-1 derivative NN2211 ameliorates glycemia and increases beta-cell mass in diabetic mice. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2002 , 283, E745-52	6	227
69	Crystal structure of glucagon-like peptide-1 in complex with the extracellular domain of the glucagon-like peptide-1 receptor. <i>Journal of Biological Chemistry</i> , 2010 , 285, 723-30	5.4	217
68	Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist. <i>Science Translational Medicine</i> , 2018 , 10,	17.5	192
67	Small-molecule agonists for the glucagon-like peptide 1 receptor. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007 , 104, 937-42	11.5	186
66	The Discovery and Development of Liraglutide and Semaglutide. <i>Frontiers in Endocrinology</i> , 2019 , 10, 155	5.7	181
65	Expression of the GLP-1 receptor in mouse, rat, and human pancreas. <i>Journal of Histochemistry and Cytochemistry</i> , 2008 , 56, 841-51	3.4	178
64	Structure-activity and protraction relationship of long-acting glucagon-like peptide-1 derivatives: importance of fatty acid length, polarity, and bulkiness. <i>Journal of Medicinal Chemistry</i> , 2007 , 50, 6126-32	8.3	178
63	Glucagon-like peptide-1-(9-36) amide is a major metabolite of glucagon-like peptide-1-(7-36) amide after in vivo administration to dogs, and it acts as an antagonist on the pancreatic receptor. <i>European Journal of Pharmacology</i> , 1996 , 318, 429-35	5.3	173
62	Liraglutide, a long-acting glucagon-like peptide-1 analog, reduces body weight and food intake in obese candy-fed rats, whereas a dipeptidyl peptidase-IV inhibitor, vildagliptin, does not. <i>Diabetes</i> , 2007 , 56, 8-15	0.9	167
61	GLP-1 derivative liraglutide in rats with beta-cell deficiencies: influence of metabolic state on beta-cell mass dynamics. <i>British Journal of Pharmacology</i> , 2003 , 140, 123-32	8.6	155
60	Glucagon-like peptide-1: the basis of a new class of treatment for type 2 diabetes. <i>Journal of Medicinal Chemistry</i> , 2004 , 47, 4128-34	8.3	152
59	The long-acting glucagon-like peptide-1 analogue, liraglutide, inhibits beta-cell apoptosis in vitro. <i>Biochemical and Biophysical Research Communications</i> , 2005 , 330, 577-84	3.4	147

58	A long-acting glucagon-like peptide-1 analogue attenuates induction of plasminogen activator inhibitor type-1 and vascular adhesion molecules. <i>Journal of Endocrinology</i> , 2009 , 201, 59-66	4.7	141
57	A GLP-1 receptor agonist liraglutide inhibits endothelial cell dysfunction and vascular adhesion molecule expression in an ApoE ^{-/-} mouse model. <i>Diabetes and Vascular Disease Research</i> , 2011 , 8, 117-24	3.3	127
56	Long-term characterization of the diet-induced obese and diet-resistant rat model: a polygenetic rat model mimicking the human obesity syndrome. <i>Journal of Endocrinology</i> , 2010 , 206, 287-96	4.7	126
55	Liraglutide: short-lived effect on gastric emptying -- long lasting effects on body weight. <i>Diabetes, Obesity and Metabolism</i> , 2012 , 14, 531-8	6.7	120
54	The GLP-1 Analogs Liraglutide and Semaglutide Reduce Atherosclerosis in ApoE and LDLr Mice by a Mechanism That Includes Inflammatory Pathways. <i>JACC Basic To Translational Science</i> , 2018 , 3, 844-857	8.7	108
53	The human GLP-1 analog liraglutide and the pancreas: evidence for the absence of structural pancreatic changes in three species. <i>Diabetes</i> , 2012 , 61, 1243-9	0.9	106
52	Expression and distribution of glucagon-like peptide-1 receptor mRNA, protein and binding in the male nonhuman primate (<i>Macaca mulatta</i>) brain. <i>Endocrinology</i> , 2015 , 156, 255-67	4.8	103
51	The GLP-1 Receptor Agonist Liraglutide Improves Memory Function and Increases Hippocampal CA1 Neuronal Numbers in a Senescence-Accelerated Mouse Model of Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2015 , 46, 877-88	4.3	100
50	Semaglutide lowers body weight in rodents via distributed neural pathways. <i>JCI Insight</i> , 2020 , 5,	9.9	94
49	Discovery and structure-activity relationship of the first non-peptide competitive human glucagon receptor antagonists. <i>Journal of Medicinal Chemistry</i> , 1998 , 41, 5150-7	8.3	92
48	Different domains of the glucagon and glucagon-like peptide-1 receptors provide the critical determinants of ligand selectivity. <i>British Journal of Pharmacology</i> , 2003 , 138, 787-94	8.6	83
47	GLP-1 receptor agonists and the thyroid: C-cell effects in mice are mediated via the GLP-1 receptor and not associated with RET activation. <i>Endocrinology</i> , 2012 , 153, 1538-47	4.8	77
46	Liraglutide, a once-daily human glucagon-like peptide-1 analog, minimizes food intake in severely obese minipigs. <i>Obesity</i> , 2007 , 15, 1710-6	8	77
45	Optimization of alkylidene hydrazide based human glucagon receptor antagonists. Discovery of the highly potent and orally available 3-cyano-4-hydroxybenzoic acid [1-(2,3,5,6-tetramethylbenzyl)-1H-indol-4-ylmethylene]hydrazide. <i>Journal of Medicinal Chemistry</i> , 2004 , 47, 1117-27	8.3	77
44	The effects of 13 wk of liraglutide treatment on endocrine and exocrine pancreas in male and female ZDF rats: a quantitative and qualitative analysis revealing no evidence of drug-induced pancreatitis. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2012 , 303, E253-64	6	69
43	Liraglutide: the therapeutic promise from animal models. <i>International Journal of Clinical Practice</i> , 2010 , 64, 4-11	2.9	68
42	GLP-1 analogue, Liraglutide protects human umbilical vein endothelial cells against high glucose induced endoplasmic reticulum stress. <i>Regulatory Peptides</i> , 2012 , 174, 46-52		65
41	Liraglutide, a long-acting human glucagon-like peptide 1 analogue, improves human islet survival in culture. <i>Transplant International</i> , 2010 , 23, 259-65	3	65

40	The truncated metabolite GLP-2 (3-33) interacts with the GLP-2 receptor as a partial agonist. <i>Regulatory Peptides</i> , 2002 , 103, 9-15		65
39	Three distinct epitopes on the extracellular face of the glucagon receptor determine specificity for the glucagon amino terminus. <i>Journal of Biological Chemistry</i> , 2003 , 278, 28005-10	5.4	61
38	NN2211: a long-acting glucagon-like peptide-1 derivative with anti-diabetic effects in glucose-intolerant pigs. <i>European Journal of Pharmacology</i> , 2002 , 451, 217-25	5.3	57
37	Chronic administration of the glucagon-like peptide-1 analog, liraglutide, delays the onset of diabetes and lowers triglycerides in UCD-T2DM rats. <i>Diabetes</i> , 2010 , 59, 2653-61	0.9	53
36	Small molecule ago-allosteric modulators of the human glucagon-like peptide-1 (hGLP-1) receptor. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2007 , 17, 5472-8	2.9	52
35	The GLP-1 receptor agonist liraglutide reduces pathology-specific tau phosphorylation and improves motor function in a transgenic hTauP301L mouse model of tauopathy. <i>Brain Research</i> , 2016 , 1634, 158-170	3.7	50
34	New beta-alanine derivatives are orally available glucagon receptor antagonists. <i>Journal of Medicinal Chemistry</i> , 2007 , 50, 113-28	8.3	49
33	Characterization of the Glucagonlike Peptide-1 Receptor in Male Mouse Brain Using a Novel Antibody and In Situ Hybridization. <i>Endocrinology</i> , 2018 , 159, 665-675	4.8	46
32	The human GLP-1 analogs liraglutide and semaglutide: absence of histopathological effects on the pancreas in nonhuman primates. <i>Diabetes</i> , 2014 , 63, 2486-97	0.9	43
31	Identification of alkylidene hydrazides as glucagon receptor antagonists. <i>Journal of Medicinal Chemistry</i> , 2001 , 44, 3141-9	8.3	43
30	Novel glucagon receptor antagonists with improved selectivity over the glucose-dependent insulinotropic polypeptide receptor. <i>Journal of Medicinal Chemistry</i> , 2008 , 51, 5387-96	8.3	41
29	GLP-1 Induces Barrier Protective Expression in Brunner's Glands and Regulates Colonic Inflammation. <i>Inflammatory Bowel Diseases</i> , 2016 , 22, 2078-97	4.5	40
28	The once-daily human GLP-1 analog, liraglutide, reduces olanzapine-induced weight gain and glucose intolerance. <i>Schizophrenia Research</i> , 2008 , 103, 94-103	3.6	39
27	Human glucagon receptor antagonists based on alkylidene hydrazides. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2002 , 12, 663-6	2.9	36
26	Integrated Brain Atlas for Unbiased Mapping of Nervous System Effects Following Liraglutide Treatment. <i>Scientific Reports</i> , 2018 , 8, 10310	4.9	34
25	Porcine marginal mass islet autografts resist metabolic failure over time and are enhanced by early treatment with liraglutide. <i>Endocrinology</i> , 2009 , 150, 2145-52	4.8	34
24	Human glucagon receptor antagonists with thiazole cores. A novel series with superior pharmacokinetic properties. <i>Journal of Medicinal Chemistry</i> , 2009 , 52, 2989-3000	8.3	30
23	Long-Term Treatment with Liraglutide, a Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist, Has No Effect on β Amyloid Plaque Load in Two Transgenic APP/PS1 Mouse Models of Alzheimer's Disease. <i>PLoS ONE</i> , 2016 , 11, e0158205	3.7	28

22	Characterization of liraglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, in rat partial and full nigral 6-hydroxydopamine lesion models of Parkinson's disease. <i>Brain Research</i> , 2016 , 1646, 354-365	3.7	24
21	Functional importance of GLP-1 receptor species and expression levels in cell lines. <i>Regulatory Peptides</i> , 2012 , 175, 21-9		22
20	Long-acting glucagon-like peptide-1 receptor agonists have direct access to and effects on pro-opiomelanocortin/cocaine- and amphetamine-stimulated transcript neurons in the mouse hypothalamus. <i>Journal of Diabetes Investigation</i> , 2016 , 7 Suppl 1, 56-63	3.9	22
19	Glucagon-like peptide-1 receptor expression in <i>Xenopus</i> oocytes stimulates inositol trisphosphate-dependent intracellular Ca ²⁺ mobilization. <i>FEBS Letters</i> , 1998 , 425, 277-80	3.8	18
18	Glucagon-like peptide-1 receptor expression in the human eye. <i>Diabetes, Obesity and Metabolism</i> , 2018 , 20, 2304-2308	6.7	17
17	A genetic map of the mouse dorsal vagal complex and its role in obesity. <i>Nature Metabolism</i> , 2021 , 3, 530-545	14.6	17
16	Quantitative whole-brain 3D imaging of tyrosine hydroxylase-labeled neuron architecture in the mouse MPTP model of Parkinson's disease. <i>DMM Disease Models and Mechanisms</i> , 2019 , 12,	4.1	16
15	Immunohistochemical assessment of glucagon-like peptide 1 receptor (GLP-1R) expression in the pancreas of patients with type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2017 , 19, 705-712	6.7	14
14	A survey of the mouse hindbrain in the fed and fasted states using single-nucleus RNA sequencing. <i>Molecular Metabolism</i> , 2021 , 53, 101240	8.8	13
13	Liraglutide, but not vildagliptin, restores normoglycaemia and insulin content in the animal model of type 2 diabetes, <i>Psammomys obesus</i> . <i>Regulatory Peptides</i> , 2010 , 160, 106-14		11
12	Distribution and ultrastructural localization of the glucagon-like peptide-1 receptor (GLP-1R) in the rat brain. <i>Brain Structure and Function</i> , 2021 , 226, 225-245	4	10
11	Transmembrane Helix 2 and 7 are important for small molecule-mediated activation of the GLP-1 receptor. <i>Pharmacology</i> , 2011 , 88, 340-8	2.3	8
10	Development of a cysteine-deprived and C-terminally truncated GLP-1 receptor. <i>Peptides</i> , 2013 , 49, 100-8	3.8	6
9	Glucagon-Like Peptide-1 Regulates the Proopiomelanocortin Neurons of the Arcuate Nucleus both Directly and Indirectly via Presynaptic Action. <i>Neuroendocrinology</i> , 2021 , 111, 986-997	5.6	5
8	Comment on: Butler et al. A critical analysis of the clinical use of incretin-based therapies: are the GLP-1 therapies safe? <i>Diabetes Care</i> 2013;36:2118-2125. <i>Diabetes Care</i> , 2013 , 36, e213	14.6	4
7	Comment on Andersen et al, pancreatitis-diabetes-pancreatic cancer: summary of an NIDDK-NCI workshop. <i>Pancreas</i> , 2014 , 43, 657	2.6	2
6	Liraglutide, a GLP-1 Analogue to Treat Diabetes 2010 , 333-357		2
5	A survey of the mouse hindbrain in the fed and fasted state using single-nucleus RNA sequencing		1

4	Treatment with glucagon-like peptide-1 receptor agonists and incidence of dementia: Data from pooled double-blind randomized controlled trials and nationwide disease and prescription registers.. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2022 , 8, e12268	6	1
3	Catalytic Antibodies with Perhydrolytic Activity. <i>Biocatalysis and Biotransformation</i> , 1995 , 13, 65-75	2.5	0
2	Leveraging human genetic data to investigate the cardiometabolic effects of glucose-dependent insulinotropic polypeptide signalling. <i>Diabetologia</i> , 2021 , 64, 2773-2778	10.3	0
1	Lixisenatide in the treatment of Type 2 diabetes. <i>Expert Review of Endocrinology and Metabolism</i> , 2014 , 9, 197-199	4.1	